Printer Friendly

ONCOGENE SCIENCE ISSUED PATENT FOR TGF BETA-3

 UNIONDALE, N.Y., Dec. 7 /PRNewswire/ -- Oncogene Science, Inc. (NASDAQ-NMS: ONCS), announced today that it has received a patent related to Transforming Growth Factor Beta-3. The Patent (No. 5,262,319), entitled "A method of obtaining bone marrow free of tumor cells using Transforming Growth Factor Beta-3," is the first U.S. patent issued to the company relating to TGF Beta-3. Earlier this year the company received a grant of a European patent claiming composition of matter of TGF Beta-3 (also referred to as TGI).
 A major problem in autologous bone marrow transplantation is protecting the normal cells from the effects of chemotherapeutic agents used to kill tumor cells. TGFB3, inhibiting the proliferation of normal hematopoietic stem cells (the progenitors in blood cells) without affecting the tumor cells, enhancing their survival after treatment with a chemotherapeutic agent to kill the tumor cells. The claimed method is useful in ex-vivo treatment of bone marrow cells to purge the cell population of actively dividing tumor cells. These purged bone marrow cells can then be reintroduced into the patient to reform the hematopoietic stem cell population.
 "This is the first U.S. issued patent with claims to TGF Beta-3. The company has filed extensive patent applications in this area," said Gary E. Frashier, President and Chief Executive Officer. "We are actively pursuing the commercialization of this biological for use as a chemoprotectant and in wound healing with our collaborative partners, Pfizer and Ciba-Geigy."
 Oncogene Science, Inc. is a biopharmaceutical company, which uses its proprietary gene transcription and oncogene-related technologies to develop products for the treatment and diagnosis of cancer and other cell control-linked diseases.
 -0- 12/7/93
 /CONTACT: Robert L. Van Nostrand, vice president, finance and administration of Oncogene Science, Inc., 516-222-0023/
 (ONCS)


CO: Oncogene Science, Inc. ST: New York IN: MTC SU:

GK-PS -- NY029 -- 1224 12/07/93 11:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 7, 1993
Words:310
Previous Article:ONCOGENE SCIENCE ISSUED PATENT FOR RAS ONCOGENE
Next Article:NUVEEN FUND DIRECTORS APPROVE 2 FOR 1 SPLIT OF MUNIPREFERRED; TWO NEW NUVEEN MUNIPREFERRED CARRY $25,000 OFFERING PRICE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters